Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice

C J Hoesley; M S Saag; A Chatham; J M Kilby

doi:10.1086/318143

Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice

Clin Infect Dis. 2000 Oct;31(4):1095-7. doi: 10.1086/318143.

Authors

C J Hoesley¹, M S Saag, A Chatham, J M Kilby

Affiliation

¹ Division of Infectious Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-2050, USA.

PMID: 11049795
DOI: 10.1086/318143

Abstract

Because there is limited information about suppression of virus loads (determined by current "ultrasensitive" assays) in patients receiving nucleoside reverse-transcriptase inhibitors (NRTIs) alone, we reviewed our experience in clinical practice with patients who had virus loads of <25 copies/mL after >1 year of treatment with dual NRTIs.

MeSH terms

Adult
Anti-HIV Agents / therapeutic use*
Female
HIV Infections / drug therapy*
HIV Infections / virology*
HIV-1 / drug effects*
HIV-1 / isolation & purification
Humans
Male
RNA, Viral / blood*
Reverse Transcriptase Inhibitors / therapeutic use*
Time Factors
Viremia / drug therapy

Substances

Anti-HIV Agents
RNA, Viral
Reverse Transcriptase Inhibitors